MajorVitamin K antagonist anticoagulants×Class III antiarrhythmics (Vaughan Williams)
Updated · Methodology
Mechanism
Acenocoumarol is a coumarin derivative and vitamin K antagonist, and in the liver CYP2C9 is the main enzyme that metabolises it (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Amiodarone and its metabolite desethylamiodarone inhibit CYP1A1, CYP1A2, CYP2C9, CYP2D6 and CYP3A4. According to the Spanish amiodarone SmPCs, amiodarone raises the levels of coumarin oral anticoagulants and can potentiate their effect (amiodarone SmPCs, AEMPS). The acenocoumarol SmPCs, both the originator and a generic, also list amiodarone among drugs that can potentiate its anticoagulant effect (acenocoumarol SmPCs, AEMPS). For warfarin, the US amiodarone label reports a 100% rise in prothrombin time after 3–4 days of combined use (amiodarone prescribing information, US Food and Drug Administration, FDA). The documents give no such figures for acenocoumarol.
Symptoms
According to the Spanish amiodarone SmPCs, combining amiodarone with oral anticoagulants can increase the risk of bleeding. Amiodarone interactions can still appear for several months after it is stopped (amiodarone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). For warfarin, the US amiodarone label warns of serious or fatal bleeding (amiodarone prescribing information, US Food and Drug Administration, FDA). Acenocoumarol can cause serious or fatal bleeding, including haemorrhagic shock. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints, as well as fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain (acenocoumarol SmPC, AEMPS).
Management
The combination is not contraindicated, but with amiodarone the acenocoumarol dose needs review and coagulation needs more frequent checks. According to the Spanish amiodarone SmPCs, check the prothrombin time and the international normalised ratio (INR) more often than usual and adjust the oral anticoagulant dose during and after amiodarone treatment (amiodarone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The generic amiodarone SmPC states that the coumarin dose should be reduced accordingly (amiodarone SmPC, AEMPS). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week, both when amiodarone is added and when it is stopped (acenocoumarol SmPCs, AEMPS). Amiodarone interactions can persist for several months after it is stopped, so INR checks and acenocoumarol dose adjustment continue after the end of the course (amiodarone SmPC, AEMPS; amiodarone prescribing information, US Food and Drug Administration, FDA). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days (acenocoumarol SmPC, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt it and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Amiodarona (nº registro 81291), sección 4.5 (2022)– AEMPS, CIMA, nº registro 81291, revisión 06/2022, sección 4.5
- AEMPS: Ficha técnica: Amiodarona, Trangorex 200 mg (nº registro 48048), secciones 4.3, 4.4 y 4.5 (2022)– AEMPS, CIMA, nº registro 48048, revisión 08/2022, secciones 4.3, 4.4 y 4.5
- FDA: Pacerone (amiodarone) prescribing information (2025)– FDA, DailyMed setid 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (Upsher-Smith Laboratories), version 27, revised 07/2025, sections 5.4 and 7 (Table 1)
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.4 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.4 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.4
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.2 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.2 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.2